背景介绍 A proliferation-inducing ligand (APRIL, TNSF13 or CD256) and B-cell maturation antigen (BCMA, also known as TNFRSF17 or CD269) create a signaling pathway that participates in the regulation of B-cell development, autoimmunity and long-term plasma cell survival. APRIL expression is significantly elevated in multiple myeloma (MM) and it has been demonstrated that activation of BCMA by APRIL promotes tumor growth, chemoresistance and immunosuppression in the bone marrow microenvironment. Anti-APRIL monoclonal antibodies have been recently progressed to clinical trials for MM. 产品介绍 The BCMA:APRIL[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of BCMA:APRIL. The key to this kit is the high sensitivity of detection of biotin-labeled APRIL by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, BCMA is coated on a 96-well plate. Next, biotinylated APRIL is incubated with BCMA on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can be measured using a chemiluminescence reader.